[FAV-Africa: a polyvalent antivenom serum used in Africa and Europe].

A Wolf, C Mazenot, S Spadoni, F Calvet, J P Demoncheaux
{"title":"[FAV-Africa: a polyvalent antivenom serum used in Africa and Europe].","authors":"A Wolf,&nbsp;C Mazenot,&nbsp;S Spadoni,&nbsp;F Calvet,&nbsp;J P Demoncheaux","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>FAV-Afrique is a polyvalent snake antivenom, elaborated by immunisation of horses with venom from 10 different snake species among the most dangerous in Africa and belonging to Elapidae and Viperidea families. Only F(ab')2 fragments are kept and purified. This serum is able to decrease the quantity of circulating venom and therefore its toxicity. Its use is indicated as soon as the first signs of poisoning are observed (local oedema). Twenty millimetres are administrated via intra-venous route whatever the weight of the patient. Re-administration may be performed if improvement is not sufficient. Treatment should be initiated as soon as possible but can be realized as long as the symptoms are present. Side effects (allergy) should be considered but balanced with the seriousness of poisoning. There is no absolute contraindication or drug interaction reported with FAV-Africa. It is authorized and distributed in several African countries and has a temporary regulatory approval in France. The major limits to its use are high cost and storage conditions (maximum 36 months between +2 degrees C and +8 degrees C). In the future, the new serum Antivipmyn Africa, available as a freeze-dried product, which can be preserved at room temperature, should improve storage conditions and availability of treatment, especially in rural Africa.</p>","PeriodicalId":18423,"journal":{"name":"Medecine tropicale : revue du Corps de sante colonial","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2011-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medecine tropicale : revue du Corps de sante colonial","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

FAV-Afrique is a polyvalent snake antivenom, elaborated by immunisation of horses with venom from 10 different snake species among the most dangerous in Africa and belonging to Elapidae and Viperidea families. Only F(ab')2 fragments are kept and purified. This serum is able to decrease the quantity of circulating venom and therefore its toxicity. Its use is indicated as soon as the first signs of poisoning are observed (local oedema). Twenty millimetres are administrated via intra-venous route whatever the weight of the patient. Re-administration may be performed if improvement is not sufficient. Treatment should be initiated as soon as possible but can be realized as long as the symptoms are present. Side effects (allergy) should be considered but balanced with the seriousness of poisoning. There is no absolute contraindication or drug interaction reported with FAV-Africa. It is authorized and distributed in several African countries and has a temporary regulatory approval in France. The major limits to its use are high cost and storage conditions (maximum 36 months between +2 degrees C and +8 degrees C). In the future, the new serum Antivipmyn Africa, available as a freeze-dried product, which can be preserved at room temperature, should improve storage conditions and availability of treatment, especially in rural Africa.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[FAV-Africa:一种在非洲和欧洲使用的多价抗蛇毒血清]。
FAV-Afrique是一种多价抗蛇毒血清,通过将非洲最危险的10种不同蛇的毒液免疫马而制成,这些蛇属于Elapidae和Viperidea家族。只有F(ab')2片段被保留和纯化。这种血清能够减少循环毒液的数量,因此它的毒性。一旦观察到中毒的最初迹象(局部水肿),就应立即使用。无论病人的体重如何,通过静脉注射20毫米。如果改善不够,可以重新给药。应尽快开始治疗,但只要出现症状就可以实现治疗。应考虑副作用(过敏),但要与中毒的严重程度相平衡。没有绝对禁忌症或药物相互作用的报道与FAV-Africa。它已在几个非洲国家获得授权和销售,并在法国获得临时监管批准。其使用的主要限制是成本高和储存条件(在+2℃至+8℃之间最长36个月)。未来,非洲的新型血清Antivipmyn将以冻干产品的形式提供,可在室温下保存,这将改善储存条件和治疗的可获得性,特别是在非洲农村。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
[Papua New Guinea]. [Japanese encephalitis]. [Chronic rheumatic manifestations following chikungunya virus infection: clinical description and therapeutic considerations]. [Physiopathology of chronic arthritis following chikungunya infection in man]. [Severe forms of chikungunya virus infection in a pediatric intensive care unit on Reunion Island].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1